title: Effects of exendin-4 on islets from type 2 diabetes patients.
abstract: Exendin-4 is a dipeptidyl peptidase IV (DPP-IV)-resistant glucagon-like peptide 1 (GLP-1) mimetic and its synthetic counterpart, exenatide, is being used in the therapy of type 2 diabetes (T2DM). No information, however, is currently available as for the direct action of exendin-4 on human T2DM islets. In the present study, we exposed pancreatic islets prepared from non-diabetic and T2DM subjects to exendin-4 for 48 h and found that the compound had several, direct beneficial actions on insulin secretion and the expression of genes involved in beta-cell function and differentiation.
authors.forename: R
authors.initials: R
authors.lastname: Lupi
authors.forename: R
authors.initials: R
authors.lastname: Mancarella
authors.forename: S
authors.initials: S
authors.lastname: Del Guerra
authors.forename: M
authors.initials: M
authors.lastname: Bugliani
authors.forename: S
authors.initials: S
authors.lastname: Del Prato
authors.forename: U
authors.initials: U
authors.lastname: Boggi
authors.forename: F
authors.initials: F
authors.lastname: Mosca
authors.forename: F
authors.initials: F
authors.lastname: Filipponi
authors.forename: P
authors.initials: P
authors.lastname: Marchetti
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects; D007515:Islets of Langerhans / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000494:pharmacology*; D014688:Venoms / Q000494:pharmacology*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D014688:Venoms; D000077270:Exenatide